Shilpa Medicare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

Results View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹442.70

prior close

₹427.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-1.1% vs market

Pharmaceuticals peers, median of 147sector+0.1%-1.3% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.7

10m

+3.3

15m

+5.0

30m

+4.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-0.1-1.1+0.1-1.3

Next day

-0.3+0.2-0.5-0.0-0.3

+0.8+0.6+0.1+0.8-0.1

+1.4+0.9+0.5+0.3+1.1

+0.2+1.0-0.8+0.0+0.2

-1.3+0.7-2.0-0.6-0.7

+2.3+1.8+0.5-0.1+2.3

15d

+5.5+1.7+3.8-0.9+6.4

-2.6+3.1-5.7-0.6-2.1

+0.1+1.7-1.6+0.6-0.5

-4.0-1.0-3.0-2.9-1.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare Limited has submitted its financial results to the stock exchange for the quarter and financial year ended March 31, 2025. This is a standard regulatory filing indicating the company has filed its audited/full-year results with NSE. The announcement itself does not contain any detailed financial figures, segment-wise performance, or management commentary. Investors will need to refer to the actual results document for revenue, profit, and margin details.

Likely market impact

No immediate price impact can be assessed from this filing alone, as it is merely a confirmation of result submission. Shareholders should review the detailed financial results and earnings call commentary for actual performance insights.